FRESENIUS SE & CO KGAA agreed to a biosimilars development partnership with WUXI BIOLOGICS CAYMAN INC on Monday morning, gaining exclusive access to 37 pipeline candidates. The German healthcare group will target originator sales exceeding €370 billion ($414 billion) over the next decade through the agreement. The collaboration expands the company's molecule count from 29 to as many as 66 by the next decade.
Fresenius Agrees Biosimilars Deal
Fresenius has signed a development agreement with WuXi Biologics for exclusive access to up to 37 biosimilar candidates over the next decade. The partnership expands the German healthcare group's pipeline and supports its long-term biopharma ambitions.
Xurve View
Insights:
Xurve View









